Poxel S.A.
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the tr… Read more
Poxel S.A. (0RA2) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.123x
Based on the latest financial reports, Poxel S.A. (0RA2) has a cash flow conversion efficiency ratio of -0.123x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€7.54 Million) by net assets (€-61.40 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Poxel S.A. - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Poxel S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Poxel S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Poxel S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hanoi Plastics JSC
VN:NHH
|
N/A |
|
Cocrystal Pharma Inc
NASDAQ:COCP
|
-0.202x |
|
Kavango Resources Plc
PINK:KVGOF
|
-0.224x |
|
Agripure Holdings Public Company Limited
BK:APURE
|
-0.003x |
|
Aurora Labs Ltd
AU:A3D
|
-1.442x |
|
Huayi Tencent Entertainment Company Limited
PINK:HUYTF
|
N/A |
|
FSBM Holdings Bhd
KLSE:9377
|
0.036x |
|
LLORENTE + CUENCA EO -01
F:91P
|
N/A |
Annual Cash Flow Conversion Efficiency for Poxel S.A. (2011–2024)
The table below shows the annual cash flow conversion efficiency of Poxel S.A. from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-58.94 Million | €-17.61 Million | 0.299x | +4.88% |
| 2023-12-31 | €-49.08 Million | €-13.98 Million | 0.285x | -76.18% |
| 2022-12-31 | €-18.24 Million | €-21.81 Million | 1.196x | +158.09% |
| 2021-12-31 | €8.21 Million | €-16.89 Million | -2.059x | -114.90% |
| 2020-12-31 | €26.88 Million | €-25.75 Million | -0.958x | -45.94% |
| 2019-12-31 | €39.14 Million | €-25.69 Million | -0.656x | -671.83% |
| 2018-12-31 | €55.78 Million | €-4.74 Million | -0.085x | -120.23% |
| 2017-12-31 | €19.33 Million | €8.13 Million | 0.420x | +187.86% |
| 2016-12-31 | €39.39 Million | €-18.85 Million | -0.479x | -80.88% |
| 2015-12-31 | €38.03 Million | €-10.06 Million | -0.265x | -111.07% |
| 2014-12-31 | €-2.55 Million | €-6.09 Million | 2.390x | +614.70% |
| 2013-12-31 | €-20.01 Million | €-6.69 Million | 0.334x | +101.87% |
| 2012-12-31 | €315.03K | €-5.64 Million | -17.912x | -1489.45% |
| 2011-12-31 | €7.35 Million | €-8.28 Million | -1.127x | -- |